EJC Supplements
Volume 5, Issue 2 , Pages 5-12 , July 2007

Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients

  • Giampaolo Bucaneve

      Affiliations

    • Istituto di Medicina Interna e Scienze Oncologiche, Azienda Ospedaliera di Perugia, Policlinico Monteluce, 06100 Perugia, Italy
    • Corresponding Author InformationCorresponding author: Tel.: +39 075 5724160; fax: +39 075 5783444.
    • ,
  • Elio Castagnola

      Affiliations

    • Unità di Malattie Infettive, Dipartimento di Ematologia e Oncologia, Ospedale “G.Gaslini”, Genova, Italy
    • ,
  • Claudio Viscoli

      Affiliations

    • Clinica Malattie Infettive, Università di Genova, Azienda Ospedale-Università “San Martino”, Genova, Italy
    • ,
  • Leonard Leibovici

      Affiliations

    • Department of Medicine “E. Rabin” Medical Center, Beilinson Campus Petah-Tiqva, Israel
    • ,
  • Francesco Menichetti

      Affiliations

    • Unità di Malattie Infettive, Ospedale Cisanello, Pisa, Italy

Received 14 May 2007 ,Revised 6 June 2007 ,Accepted 11 June 2007.

References 

  1. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751
  2. Sleijfer DT, Mulder NH, de vries-Hospers HG, et al. Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer. 1980;16:859–869
  3. Karp JE, Merz WG, Hendricksen C, et al. Oral norfloxacin for prevention of Gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1987;106:1–7
  4. Hartlapp JH. Antimicrobial prophylaxis in immunocompromised patients. Drugs. 1987;34(Suppl. 1):131–133
  5. Lew MA, Kehoe K, Ritz J, et al. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation. 1991;51:630–636
  6. Sampi K, Maseki N, Hattori M. A comparison of nystatin with norfloxacin for prevention of infection after consolidation therapy in patients with acute leukemia or autologous bone marrow transplantation: a randomized study. Gan to Kagaku Ryoho. 1992;19:823–826[in Japanese]
  7. Shhroeder M, Schessel C, Selbach J, et al. Antibiotic prophylaxis with gyrase inhibitors during cytostatically induced granulocytopenias in patients with solid tumors a double-blind prospective randomized study. Onkologie. 1992;15:476–479
  8. Maiche AG, Muhonen T. Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients. Eur J Cancer. 1993;29A:1403–1405
  9. Talbot GH, Casileth PA, Paradiso L, et al. Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group. Antimicrob Agents Chemother. 1993;37:474–482
  10. Yamada T, Dan K, Nomura T. Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B. Intern Med. 1993;2:710–715
  11. Brodsky AL, Minissale CJ, Melero MJ, et al. Prophylaxis with fluoroquinolones in patients with neutropenia. Medicina (B Aires). 1993;53:401–407
  12. Carlson JW, Fowler JM, Mitchell SK, et al. Chemoprophylaxis with ciprofloxacin in ovarian cancer patients receiving paclitaxel: a randomized trial. Gynecol Oncol. 1997;65:325–329
  13. Casali A, Veri C, Paoletti G, et al. Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin. Chemioterapia. 1988;7:327–329
  14. Thomas X, Troncy J, Belhabri A, et al. Effectiveness of combined vancomycin and pefloxacine in gastrointestinal decontamination for preventing infections after chemotherapy-induced bone marrow aplasia. A randomized double-blind study. Presse Med. 2000;29:1745–1751
  15. Tjan-HeiJnen VC, Postmus PE, Ardizzoni A, et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol. 2001;12:1359–1368
  16. Nenova IS, Ananostev NH, Goranov SE, et al. Fluoroquinolone prophylaxis for bacterial infections in neutropenic patients with hematologic malignancies. Folia Med (Plovdiv). 2001;43:40–45
  17. Tsutani H, Imamura S, Ueda T, et al. Prophylactic use of ofloxacin in granulocytopenic patients with hematological malignancies during post-remission chemotherapy. Intern Med. 1992;31:319–324
  18. Lee DG, Choi SM, Choi JH, et al. Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial. Korean J Intern Med. 2002;17:38–44
  19. Castagnola E, Haupt R, Micozzi A, et al. Differences in the proportions of fluoroquinolone-resistant Gram-negative bacteria isolated from bacteraemic children with cancer in two Italian centres. Clin Microbiol Infect. 2005;11:505–507
  20. Bucaneve G, Micozzi A, Menicheti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–987
  21. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353:988–998
  22. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142:979–995
  23. van de Wetering MD, de Witte MA, Kremer LCM, et al. Efficay of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer. 2005;41:1372–1382
  24. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol. 1998;16:1179–1187
  25. Cruciani M, Randazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis. 1996;23:795–805
  26. Cruciani M, Malena M, Bosco O, et al. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol. 2003;21:4127–4137
  27. Leibovici L, Paul M, Cullen M, et al. Antibiotic prophylaxis in neutropenic patients: new evidences, practical decisions. Cancer. 2006;107:1743–1751
  28. Kern WV, Andriof E, Oethinger M, et al. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother. 1994;38:681–687
  29. Carratala J, Fernandez-Sevilla A, Tubau F, et al. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis. 1995;20:557–560[discussion 561–3]
  30. Somolinos N, Arranz R, Del Rey MC, et al. Superinfections by Escherichia coli resistant to fluoroquinolones in immunocompromised patients. J Antimicrob Chemother. 1992;30:730–731
  31. Razonable RR, Litzow MR, Khaliq Y, et al. Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin. Clin Infect Dis. 2002;34:1469–1474
  32. Baden LR. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med. 2005;353:1052–1054
  33. Martino R, Subira M, Altes A, et al. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity. Acta Haematol. 1998;99:206–211
  34. Kern WV, Klose K, Jellen Ritter AS, et al. Fluoroquinolones resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis. 2005;24:111–118
  35. The GIMEMA Infection Program . Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med. 1991;115:7–12
  36. D’Antonio D, Piccolomini R, Iacone A, et al. Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies. J Antimicrob Chemother. 1994;33:837–844
  37. Carlens S, Ringden O, Aschan J, et al. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination. Clin Transplant. 1998;12:84–92
  38. Xie HJ, Broberg U, Griskevivius L, et al. Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome p450 genes by ciprofloxacin. Bone Marrow Transplant. 2003;31:197–203
  39. Afsharian P, Mollgard L, Hassan Z, et al. The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma. Eur J Haematol. 2005;75:206–211

☆ The ECIL-1 is a common initiative of the following groups or organisations: Infectious Diseases Working Party of the European Blood and Marrow Transplantation Group (EBMT-IDWP), Infectious Diseases Group of the European Organisation for Research and Treatment of Cancer (EORTC-IDG), European Leukaemia Net (ELN) (EU Grant No. LSHC-CT-2004), and International Immunocompromised Host Society (ICHS).

PII: S1359-6349(07)00004-3

doi: 10.1016/j.ejcsup.2007.06.002

EJC Supplements
Volume 5, Issue 2 , Pages 5-12 , July 2007

Article Tools

* Image Usage & Resolution